TY  - CHAP
M1  - Book, Section
TI  - Long-Acting Injectable Antipsychotics
A1  - BIGLOW, MICHAEL
A1  - FLINCHUM, MEGAN
A2  - Cohen, Henry
Y1  - 2015
N1  - 
T2  - Casebook in Clinical Pharmacokinetics and Drug Dosing
AB  - Antipsychotics  are  the  mainstay  of  drug  treatment  for  the  management  of  schizophrenia  and  other  psychotic  disorders.  The  mechanism  of  action  of  the  medication  depends  on  the  type  of  antipsychotic  with  the  older  “typical”  antipsychotics  focusing  on  the  antagonism  of  postsynaptic  dopamine  type-2  (D2)  receptors.  The  newer  “atypical”  drugs  antagonizing  both  D2  and  serotonin  type-2A  receptors  elicit  a  comparable  antipsychotic  effect  but  with  the  potential  for  lessening  iatrogenic  movement  disorders  and  improving  negative  symptoms  (e.g.,  anhedonia,  flattened  affect,  cognitive  impairment).1  The  option  of  using  depot  formulations  of  these  medications  allows  for  a  number  of  benefits  including  consistent  drug  delivery,  assured  patient  compliance,  predicable  bioavailability,  and  avoidance  of  intentional  or  accidental  overdose.2  Available  depot  formulations  exist  for  the  typical  antipsychotics  haloperidol  and  fluphenazine  and  the  atypical  antipsychotics  risperidone,  paliperidone,  and  olanzapine.  Dosing  parameters  vary  due  to  different  drug  release  mechanisms  and  intended  time  to  response.  (see  Table  11-1)  Their  role  in  therapy  has  been  established  and  they  are  recommended  for  patients  who  would  prefer  this  method  of  treatment  with  the  simplification  of  medication  administration,  who  have  a  history  of  relapse  due  to  noncompliance,  and  when  avoiding  noncompliance  is  a  clinical  priority.2,  3,  and  4  Although  patients  on  depot  antipsychotics  receive  treatment  on  a  more  consistent  and  monitored  basis,  data  are  still  limited  on  whether  depot  injections  reduce  relapse  rates  or  long-term  adverse  drug  events  compared  to  oral  antipsychotics.5,6  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - accesspharmacy.mhmedical.com/content.aspx?aid=1112257828
ER  -